Standard Therapy for Patients With Myelodysplastic Syndromes

被引：3

作者：

Al-Ameri, Ali

Cherry, Mohamad ^{[2
]}

Garcia-Manero, Guillermo

Quintas-Cardama, Alfonso ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Dept Internal Med, Hematol Oncol Sect, Oklahoma City, OK USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2011年 / 11卷 / 04期

关键词：

Azacitidine; Decitabine; Lenalidomide; MDS; Myelodysplastic syndrome; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; COLONY-STIMULATING FACTOR; LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE; FARNESYL TRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITORS; BONE-MARROW-TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; IRON CHELATION-THERAPY; PHASE-II TRIAL;

D O I：

10.1016/j.clml.2011.06.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell transplantation. Over the past decade, several novel therapeutic agents have been approved for clinical use. In this article, the current approach for the management of patients with MDS according to their risk category is described and mainly focuses on approved novel agents.

引用

页码：303 / 313

页数：11

共 87 条

[1] Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study [J].

Ades, Lionel ;

Boehrer, Simone ;

Prebet, Thomas ;

Beyne-Rauzy, Odile ;

Legros, Laurence ;

Ravoet, Christophe ;

Dreyfus, Francois ;

Stamatoullas, Aspasia ;

Chaury, Marie Pierre ;

Delaunay, Jacques ;

Laurent, Guy ;

Vey, Norbert ;

Burcheri, Sara ;

Mbida, Rose-Marie ;

Hoarau, Natacha ;

Gardin, Claude ;

Fenaux, Pierre .

BLOOD, 2009, 113 (17) :3947-3952

[2]

Alessandrino EP, 2002, HAEMATOLOGICA, V87, P1286

[3]

ANDERSON JE, 1993, BLOOD, V82, P677

[4]

[Anonymous], [No title captured]

[5] Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) [J].

Aoudjhane, M ;

Labopin, M ;

Gorin, NC ;

Shimoni, A ;

Ruutu, T ;

Kolb, HJ ;

Frassoni, F ;

Boiron, JM ;

Yin, JL ;

Finke, J ;

Shouten, H ;

Blaise, D ;

Falda, M ;

Fauser, AA ;

Esteve, J ;

Polge, E ;

Slavin, S ;

Niederwieser, D ;

Nagler, A ;

Rocha, V .

LEUKEMIA, 2005, 19 (12) :2304-2312

[6] Allogeneic stem cell transplantation for myelodysplastic syndrome [J].

Barrett, A. John ;

Savani, Bipin N. .

SEMINARS IN HEMATOLOGY, 2008, 45 (01) :49-59

[7]

BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[8] Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia [J].

Blum, William ;

Klisovic, Rebecca B. ;

Hackanson, Bjoern ;

Liu, Zhongfa ;

Liu, Shujun ;

Devine, Hollie ;

Vukosavljevic, Tamara ;

Huynh, Lenguyen ;

Lozanski, Gerard ;

Kefauver, Cheryl ;

Plass, Christoph ;

Devine, Steven M. ;

Heerema, Nyla A. ;

Murgo, Anthony ;

Chan, Kenneth K. ;

Grever, Michael R. ;

Byrd, John C. ;

Marcucci, Guido .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3884-3891

[9] A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies [J].

Bouscary, D ;

Legros, L ;

Tulliez, M ;

Dubois, S ;

Mahe, B ;

Beyne-Rauzy, O ;

Quarre, MC ;

Vassilief, D ;

Varet, B ;

Aouba, A ;

Gardembas, M ;

Giraudier, S ;

Guerci, A ;

Rousselot, P ;

Gaillard, F ;

Moreau, A ;

Rousselet, MC ;

Ifrah, N ;

Fenaux, P ;

Dreyfus, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (05) :609-618

[10] Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes [J].

Bowen, D ;

Culligan, D ;

Jowitt, S ;

Kelsey, S ;

Mufti, G ;

Oscier, D ;

Parker, J .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (02) :187-200

← 1 2 3 4 5 6 7 8 9 →